The MET RTK was initially discovered as a transforming oncogene in human osteogenic sarcoma cell lines exposed to the chemical carcinogen N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), from which it derives its name ‘MET’ [5,6]. The gene discussed is MET; the disease is osteosarcoma.